GlassScriptPhysician profile
Cary L Carpenter
NPI 1053311548
$2,749.97
in general payments reported to CMS, 2019-2025
31 companies · $505 in 2025
The $505 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2020: $414 · 2021: $688 · 2022: $90.76 · 2023: $323 · 2024: $266 · 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,093.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $764.86 | 2019-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $335.52 | 2019-2025 | Rybelsus, Ozempic, Saxenda |
| Abbvie INC. | $211.26 | 2021-2024 | Vraylar |
| Lilly USA, LLC | $157.93 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $151.08 | 2019-2021 | |
| Glaxosmithkline, LLC. | $142.95 | 2019-2023 | Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $110.75 | 2023-2025 | |
| Exact Sciences Corporation | $106.11 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $97.20 | 2021-2022 | |
| Pfizer INC. | $93.40 | 2020-2021 | |
| Allergan, INC. | $82.69 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.92 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $51.32 | 2021 | |
| Merck Sharp & Dohme LLC | $40.27 | 2019-2020 | |
| Dexcom, INC. | $30.43 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $29.88 | 2023 | Gemtesa |
| Nestle Healthcare Nutrition INC. | $29.01 | 2020-2021 | |
| Corium, LLC | $27.26 | 2023 | Azstarys |
| Biohaven Pharmaceuticals, INC. | $26.27 | 2021 | |
| Shire North American Group INC | $19.32 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $18.47 | 2021 | |
| Viatris Specialty LLC | $18.39 | 2025 | Yupelri |
| Eisai INC. | $17.41 | 2025 | |
| Ironshore Pharmaceuticals INC. | $15.69 | 2019 | |
| Phathom Pharmaceuticals, INC. | $15.62 | 2024 | Voquezna |
| Sanofi-Aventis U.S. LLC | $14.37 | 2019 | |
| Dermira, INC. | $13.98 | 2020 | |
| Boston Scientific Corporation | $13.18 | 2020 | |
| Antares Pharma, INC. | $13.07 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.17 | 2020 | |
| Adlon Therapeutics L.P. | $11.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cary Carpenter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.